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Abstract
Background: MicroRNAs (miRNAs) are known to regulate many biological processes and their dysregulation has been
associated with a variety of diseases including Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). The recent
discovery of stable and reproducible miRNA in plasma has raised the possibility that circulating miRNAs may serve as novel
diagnostic markers. The objective of this study was to determine the role of plasma miRNA in CFS/ME.
Results: Using Illumina high-throughput sequencing we identified 19 miRNAs that were differentially expressed in the
plasma of CFS/ME patients in comparison to non-fatigued controls. Following RT-qPCR analysis, we were able to confirm the
significant up-regulation of three miRNAs (hsa-miR-127-3p, hsa-miR-142-5p and hsa-miR-143-3p) in the CFS/ME patients.
Conclusion: Our study is the first to identify circulating miRNAs from CFS/ME patients and also to confirm three differentially
expressed circulating miRNAs in CFS/ME patients, providing a basis for further study to find useful CFS/ME biomarkers.
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Introduction
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/
ME) is known to affect about 1–4% of individuals worldwide [1,2].
CFS/ME is a multi-symptom disorder including profound
disabling fatigue and post-exertional sickness, cognitive distur-
bances, tender or painful lymph nodes, muscle ache and pain and
irregular sleep patterns [3]. There is evidence to suggest a
dominant disruption of immunological process in CFS/ME and
this may be characterised by reduced cytotoxic activity and
increases in regulatory T cells [4,5,6]. In addition patients with
CFS/ME may display differential expression in the mRNA and
microRNA (miRNA) genes that regulate various physiological
processes known to be dysregulated in CFS/ME including
cytotoxicity, cytokine secretion and apoptosis [4,7,8,9,10,11,12].
Despite intensive research the pathophysiology of CFS/ME is not
yet fully understood and clear diagnostic biomarkers remain
elusive.
MicroRNAs are a class of small (typically 18–25 nucleotides in
size) single-stranded, non-coding RNAs that regulate gene
expression at the post-transcriptional level [13]. Their regulatory
roles have been implicated in most biological processes including
immunological, neurological and physiological processes
[14,15,16,17]. Differential expression of miRNA has been
associated with over 300 diseases, including cancer, cardiomyop-
athies, neurological disorders and unexplained disorders such as
CFS/ME [4,18,19,20,21]. Stable and reproducible extracellular
miRNAs circulating in blood and present in other biofluids have
recently been identified (16). It has been proposed that these
miRNAs have the potential to be utilised as non-invasive novel
biomarkers for disease diagnosis and prognosis [22,23,24,25,26].
In this study, we employed high-throughput sequencing (HTS)
to globally profile circulating miRNA expression. This was
followed by confirmative reverse transcription-quantitative PCR
(RT-qPCR) to determine differential miRNA expression in CFS/
ME.
Materials and Methods
Participants
CFS/ME patients (n = 20, age = 44.566.0 years) were recruited
from a South-East Queensland patient database in Australia.
Inclusion criteria for the CFS/ME participants were according to
the American CDC 1994 case definition [26]. Non-fatigued
controls (n = 20, age = 47.366.7 years) were recruited mainly from
the general public, and were participants with no medical history
or symptoms of persistent fatigue or illness. Individuals who were
smokers, pregnant/breast-feeding or immobile were excluded
from the study, as were individuals with autoimmune, thyroid or
cardiac related disorders prior to the onset of CFS/ME. This
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project was approved by the Bond University Human Research
Ethics Committee (BUHREC), approval number R0852A. All
participants in the study provided informed and written consent
prior to involvement in the study.
Sample processing and RNA extraction
Plasma harvesting was performed immediately after peripheral
blood collection. Briefly 10 mL of whole blood was collected from
each participant into EDTA collection tubes. Plasma was
immediately separated via centrifugation at 5006g for 10 min,
and 5 mL of the plasma was transferred to a new tube and stored
at -80uC. Prior to RNA extraction, the plasma samples were
centrifuged for 10 min at 16,0006g at 4uC in order to remove any
cellular debris left in the plasma. Circulating RNA was extracted
from plasma using the miRNeasy Serum/Plasma kit (Qiagen,
Hilden, Germany) according to manufacturer’s instruction with
minor modifications. Briefly, 1 mL of plasma was incubated with
5 mL of QIAzol Lysis Reagent for 10 min. Samples were
processed using a vacuum manifold to help process the larger
quantity of plasma. An additional 80% ethanol wash step was
included and sample elution was performed twice using 15 mL of
RNase-free water. The size, quantity and quality of the extracted
circulating RNA was assessed using a small RNA chip on an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
MicroRNA profiling by HiSeq2000 sequencing
The six CFS/ME patients and six non-fatigued controls with
the highest abundance of small RNA were used for HTS. Small
RNA libraries were constructed using the TruSeq Small RNA
Sample Preparation kit (Illumina, San Diego, CA) according to the
manufacturer’s protocols. Briefly, small RNA samples (5–10 ng)
were ligated with 59 and 39 adapters, followed by reverse
transcription-PCR (RT-PCR) for cDNA library construction and
incorporation of index tags. The cDNA library fragments were
purified separated on a 6% TBE PAGE gel and 145–160 bp size
fraction containing miRNA inserts was isolated. The twelve cDNA
library samples were pooled in equimolar amounts and used for
cluster generation and sequence analysis in a single lane on an
Illumina HiSeq2000 (50 bp single read). This work was performed
at the Australian Genome Research Facility (AGRF).
Sequencing data analysis
Raw FASTQ sequences were generated and demultiplexed
using the Illumina CASAVA v1.8 pipeline. Per base sequence
quality (quality score .30) was then assessed using the FastQC
toolkit (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc). Prior to mapping the read data was pre-processed using
the UEA small RNA Workbench (http://srna-workbench.cmp.
uea.ac.uk) [27]. Briefly, the 39 adapter sequences were trimmed,
the read size filtered (16–35 nt), unique reads counted and low
abundance reads (,10 reads) discarded. Unique sequence reads
were then aligned to the human genome (hg18) and miRBase_v16
using the miRanalyzer web server tool (http://bioinfo2.ugr.es/
miRanalyzer/miRanalyzer.php) [28]. Raw reads of the sequenc-
ing data are available at the NCBI Sequence Read Archive (SRA).
Data are accessible through NCBI BioProject accession number
PRJNA219428 at http://www.ncbi.nlm.nih.gov/bioproject/.
Quantification of miRNA by RT-qPCR
The expression of eight miRNAs was validated using PerfeCTa
miRNA primers (Quanta Biosciences, Gaithersburg, MD). In
addition four miRNAs (miR-10, miR-15b, miR-16 and miR-24)
were assessed for their suitability as a stable reference gene. Briefly,
15 mL of extracted RNA were reverse transcribed into cDNA
using the NCode miRNA First-Strand cDNA Synthesis kit (Life
Technologies, Carlsbad, CA). RT-qPCR was performed as
previously described [4].
Statistical analyses
Mann-Whitney rank sum test was used in analysing differences
between the CFS/ME patients and non-fatigued controls regard-
ing age and haematological characteristics (Table 1 and 2). For
RT-qPCR analysis unpaired groups of values were compared
according to the non-parametric Mann-Whitney U test. These
data were analysed using GraphPad Prism 5 (GraphPad Software,
San Diego, CA). Differential expression of the miRNA-Seq raw
count data was assessed using the BioC/R package DESeq [29].
Due to the small sample size and the heterogeneity of the CFS/
ME phenotype we interpreted significance from the unadjusted
P-value, without the Benjamini-Hochberg method for False
Discovery (FDR) correction. Statistical significance was accepted
at P,0.05.
Results
Subject characteristics
The age of the study participants was recorded and a full blood
count performed on whole blood samples prior to plasma
separation. There were no significant differences between age or
full blood count values in the CFS/ME and control groups
(Table 1). For sequencing, a subset of six CFS/ME and six non-
fatigued control samples were selected. A significant difference in
lymphocyte and granulocyte percentages, lymphocyte count and
red blood cell distribution width between the CFS/ME and
control groups was observed in these subsets (Table 2).
Illumina high-throughput sequencing of plasma miRNA
in CFS/ME
To select for candidate plasma miRNAs differentially expressed
in CFS/ME, we performed an initial genome-wide small RNA
screening of six CFS/ME patients and six non-fatigued controls by
Illumina HTS. A total of 154,989,205 reads were generated from
a single flow cell lane on the HiSeq2000 sequencer. After
demultiplexing an average of 12 million reads per library was
obtained. Initial analysis of the library read lengths demonstrated a
bimodal distribution of reads with peaks at 22 and 32 nucleotides
(Figure S1). These populations were subsequently found to contain
miRNA and long non-coding RNA (lncRNA) sequences respec-
tively. On average 57.4% of decoded sequences were mappable,
with 97.5% of mappable reads aligning to the human genome
(hg18). Mature miRNA constituted 17% of all mapped reads,
whilst other RNA species (including lncRNA and snoRNA)
constituted 80.5% of mapped reads (Figure 1A). 75.1% of the
mapped other RNA species consisted of lncRNA known as Ro-
associated RNA Y4 (RNY4) which is the main component of the
32–33 nucleotide population. When examining unique reads,
miRNA comprised 44.3% of all unique reads mapped whilst other
RNA species comprised only 7% (Figure 1B).
MiRNA characterisation
A total of 375 mature miRNA were initially identified in one or
more samples based on sequence alignment to the miRBase
registry (release 19). The top 25 expressed miRNAs in each sample
group are listed in Table 3. Furthermore, 13 novel candidate
miRNAs were predicted, although these amounted to a very small
fraction of the total read count. However, none of these novel
Circulating MiRNAs in CFS/ME
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miRNA showed significant differences between CFS/ME and
non-fatigued controls (Table S1).
Differential expression of plasma miRNA in CFS
Differential expression of identified miRNAs from miRBase was
calculated using DESeq. A total of 19 microRNAs were
significantly dysregulated in CFS/ME compared to non-fatigued
controls (Table 4). Of the 19 differentially expressed miRNAs 16
were considered low in abundance due to a base mean count of
less than 1,000 reads, their detection was found to be unreliable for
confirmative RT-qPCR.The remaining three miRNAs (hsa-
Table 1. Characteristics of CFS/ME and non-fatigued control participants.
Parameters Non-Fatigued (n=20) CFS/ME (n=20) *P-values
Age 47.366.7 44.566.0 0.24
White Blood Cells (103/mL) 6.1961.58 5.5361.45 0.12
Lymphocytes (%) 35.8968.81 34.8066.41 0.53
Monocytes (%) 6.7261.60 6.9661.77 0.66
Granulocytes (%) 57.3968.94 58.2566.49 0.74
Lymphocytes (x103/mL) 2.1460.53 1.8960.46 0.13
Monocytes (x103/mL) 0.4160.12 0.3960.15 0.66
Granulocytes (x103/mL) 3.6461.53 3.2561.05 0.36
Red Blood Cells (x106/mL) 4.2060.36 4.1360.24 0.43
Haemoglobin (g/L) 133.6868.52 132.2067.88 0.40
Haematocrit (%) 37.1461.95 36.6762.10 0.40
Mean Cell Volume (fl) 88.8265.39 88.6962.58 0.51
Mean Cell Haemoglobin (pg) 31.9762.01 32.0261.13 0.78
Mean Corpuscular Haemoglobin Concentration (g/L) 359.9567.17 360.9566.44 0.64
Red Blood Cell Distribution Width (%) 12.5261.28 12.4460.69 0.41
Platelet (x103/mL) 231.06688.61 243.80653.20 0.38
Mean Platelet Volume (fl) 7.5960.77 7.6361.16 0.72
*Denotes statistical significance set at P,0.05.
The blood characteristics of the participants in the study are presented below following full blood count analysis.
doi:10.1371/journal.pone.0102783.t001
Table 2. Characteristics of miRNA-Seq subset of CFS/ME and non-fatigued control participants.
Parameters Non-Fatigued (n=6) CFS/ME (n=6) *P-values
Age 48.868.0 41.764.8 0.09
White Blood Cells (103/mL) 6.2360.83 5.6761.60 0.70
Lymphocytes (%) 41.3065.50 33.2766.46 0.09
Monocytes (%) 7.0261.20 6.4261.22 0.49
Granulocytes (%) 51.6865.28 60.3266.02 0.04*
Lymphocytes (x103/mL) 2.5860.53 1.8360.48 0.03*
Monocytes (x103/mL) 0.4360.08 0.3760.16 0.49
Granulocytes (x103/mL) 3.2260.49 3.4561.09 0.39
Red Blood Cells (x106/mL) 4.2460.39 4.0660.26 0.24
Haemoglobin (g/L) 134.6769.69 132.3368.76 0.49
Haematocrit (%) 37.3562.09 36.4762.32 0.49
Mean Cell Volume (fl) 88.2563.95 88.8762.15 0.94
Mean Cell Haemoglobin (pg) 31.7860.95 32.3060.80 0.24
Mean Corpuscular Haemoglobin Concentration (g/L) 360.3368.41 363.3360.37 0.49
Red Blood Cell Distribution Width (%) 12.0360.47 12.6260.37 0.03*
Platelet (x103/mL) 248.17685.41 237.17641.39 0.70
Mean Platelet Volume (fl) 7.5860.80 6.9060.86 0.24
* Denotes statistical significance set at P,0.05.
The blood characteristics of the participants chosen for sequencing analysis.
doi:10.1371/journal.pone.0102783.t002
Circulating MiRNAs in CFS/ME
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miR127-3p, hsa-miR-142-5p and hsa-miR-143-3p) were all up-
regulated in CFS/ME compared to non-fatigued controls.
RT-qPCR confirmation of plasma miRNA-Seq data
The choice of a stable reference gene is critical for accurate gene
expression analysis by RT-qPCR. Of the four putative reference
genes tested hsa-miR-16-5p was determined to be the most stably
expressed (Figure 2). To validate the RNA-Seq results (n = 6/
group) we performed RT-qPCR in an expanded sample cohort
(n = 20/group). Three differentially expressed miRNAs (hsa-
miR127-3p, hsa-miR-142-5p and hsa-miR-143-3p) and four
non-differentially expressed miRNAs (hsa-miR-21-5p, hsa-miR-
Figure 1. Read classification as predicted by miRanalyzer. Percentage of A) read count and B) unique reads mapped to mature miRNAs, other
microRNAs (ambiguous, star and hairpin), other non-coding RNAs and unmapped.
doi:10.1371/journal.pone.0102783.g001
Table 3. Top 25 most abundant miRNAs identified.
miRNA ID Rank (Non-Fatigued) Base Mean1 (Non-Fatigued) Rank (CFS/ME) Base Mean1 (CFS/ME)
hsa-miR-486-5p 1 232,025 1 206,637
hsa-miR-191-5p 2 163,282 2 161,507
hsa-miR-92a-3p 3 122,247 3 112,091
hsa-miR-22-3p 4 98,273 4 102,010
hsa-miR-30d-5p 5 64,038 5 58,586
hsa-miR-26a-5p 6 56,084 6 54,753
hsa-miR-181a-5p 7 49,098 7 37,346
hsa-miR-151a-3p 8 35,388 8 33,991
hsa-miR-423-5p 9 34,660 9 33,841
hsa-miR-16-5p 10 32,226 10 27,914
hsa-miR-150-5p 11 20,792 12 16,977
hsa-miR-126-5p 12 17,096 11 17,960
hsa-miR-25-3p 13 12,834 16 10,555
hsa-miR-28-3p 14 12,733 14 13,057
hsa-miR-30e-5p 15 12,559 13 13,146
hsa-miR-186-5p 16 11,374 17 10,153
hsa-miR-151a-5p 17 9,241 18 8,655
hsa-miR-127-3p 18 8,750 15 12,961
hsa-miR-10a-5p 19 8,093 22 6,443
hsa-miR-423-3p 20 7,619 19 7,856
hsa-miR-451a 21 6,451 23 6,292
hsa-miR-140-3p 22 6,252 25 5,895
hsa-miR-27b-3p 23 6,093 20 7,497
hsa-miR-146a-5p 24 5,994 21 7,246
hsa-miR-221-3p 25 5,749 29 4,863
1The base mean is the mean of the counts for each miRNA divided by the size factor for each condition (as calculated by DESeq).
doi:10.1371/journal.pone.0102783.t003
Circulating MiRNAs in CFS/ME
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103-3p, hsa-miR-146a-5p and hsa-miR-223-3p) were selected
and their expression levels quantified using RT-qPCR. The four
non-differentially expressed miRNAs were selected as they
previously demonstrated dysregulation in cytotoxic lymphocytes
in CFS/ME patients [3], although HTS did not identify
differential expression in plasma. All RT-qPCR results for the
remaining three miRNAs were consistent with the RNA-Seq data
(Figure 3).
Discussion
To date, screening for CFS/ME has been based on well-
established case definitions [3,30]. Profiling of circulating miRNA
levels may serve to enhance the molecular diagnosis of CFS/ME.
Using Illumina HTS, the present study identified 19 miRNAs that
were differentially expressed in CFS/ME patients. Of these, only
three were confirmed to be highly abundant in the CFS/ME
patients in comparison to the controls. These results suggest that
miR-127-3p, miR-142-5p and miR-143-3p may be implicated in
the pathogenesis of CFS/ME.
Although, there is currently no definitive source identified for
the presence of miRNAs in biofluids, blood cells in particular
reticulocytes, myeloid cells, lymphoid cells, platelets, cells from the
liver, lungs and kidneys or lysed cells may release miRNAs into the
circulation [31,32,33]. Similarly, miRNAs may be discharged into
the plasma following tissue damage for example, circulating miR-1
and miR-133a, are significantly increased following acute
myocardial infarction [34]. The miRNAs in the present study
have expressions in various tissues. MiR-127-3p is found in the
testicular and nervous system [35], miR-143-3p is expressed in the
colon [36] while miR-142-5p is expressed by cells of the immune
system [37,38]. However, both miR-142-5p and miR-143-3p are
reported to be amongst the miRNAs frequently found in plasma
and serum [32]. Over-expression of miR-142-5p has been
observed in most cancer-related and immunological disorders
[39]. This particular miRNA is abundant in most hematopoietic
cell lines and may be involved in thwarting inflammatory processes
Table 4. miRNAs differentially expressed between CFS/ME and non-fatigued controls.
miRNA ID Base Mean1 (Non-Fatigued) Base Mean1 (CFS/ME) Fold Change P-value
High-Abundance miRNAs
hsa-miR-127-3p 8,751.91 12,978.10 1.48 0.0476
hsa-miR-143-3p 2,060.61 4,439.17 2.15 0.0005
hsa-miR-142-5p 994.22 1,811.23 1.82 0.0443
Low-Abundance miRNAs
hsa-miR-331-3p 366.94 590.85 1.61 0.0277
hsa-miR-381-3p 347.35 550.72 1.59 0.0336
hsa-miR-136-3p 125.63 224.69 1.79 0.0213
hsa-miR-370 59.84 130.44 2.18 0.0051
hsa-miR-493-5p 39.87 82.49 2.07 0.0263
hsa-miR-4532 10.47 78.06 7.45 0.0002
hsa-miR-450b-5p 1.72 1.23 0.71 0.0208
hsa-miR-26a-1-3p 1.56 1.16 0.75 0.0106
hsa-mir-126* 1.39 0.91 0.65 0.0449
hsa-miR-5187-3p 1.31 1.10 0.84 0.0217
hsa-miR-641 1.07 0.78 0.73 0.0240
hsa-miR-548j 1.07 1.10 1.03 0.0446
hsa-miR-3065-3p 0.90 0.71 0.79 0.0126
hsa-miR-16-2-3p 0.82 0.71 0.87 0.0128
hsa-let-7g-3p 0.82 0.78 0.95 0.0251
hsa-miR-548ax 0.82 0.91 1.11 0.0484
1The base mean is the mean of the counts for each miRNA divided by the size factor for each condition (as calculated by DESeq).
*The complementary analog for miR-126.
doi:10.1371/journal.pone.0102783.t004
Figure 2. Expression stability values (M) of the putative
reference genes tested in plasma. The expression of four genes
was analysed to determine the most suitable reference gene.
MicroRNAs are ranked from the most stable to the least stable (left to
right). The dotted line indicates the recommended threshold value of
,1.0 for heterogeneous samples.
doi:10.1371/journal.pone.0102783.g002
Circulating MiRNAs in CFS/ME
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[40]. In Systemic Lupus Erythematosus (SLE), increased expres-
sion of miR-142-5p in CD4+T cells prevents autoimmunity while
a downregulation may result in autoreactive T cells and
hyperactive B cells [41].
MiR-142-5p is important for T cell development where it
targets SLAM associate protein (SAP). Inhibition of miR-142-5p
may increase the expression of CD84, IL-10, SAP and IgG
production [41]. CD84 is an important T cell regulatory marker as
it regulates cytokine production, function, adhesion and interac-
tion with B cells [42]. The levels of IL-10 have been shown to be
equivocal in CFS/ME patients. The cause of an increase in miR-
142-5p is unknown, however, it is likely that this may be related to
heightened Treg suppression and additional autoimmune respons-
es.
MiR-143-3p targets IgG Fcc receptor 1 and also CD64
reducing lung inflammation. It is a tumour suppressor gene and is
highly down regulated in colorectal cancer [43]. It inhibits the
oncogene KRAS [44]. Overexpression of miR-143-3p in most
cancer cells stagnates the growth of tumours and cancer cells [45]
as it may act to reduce BCL2 mRNA thereby preventing tumour
or cancer cell proliferation and promoting apoptosis [46]. miR-
143-3p has been identified as a neutrophil specific miRNA [47].
Importantly, its expression is upregulated in cases of heightened
erythropoiesis such as in polycythemia [48]. In CFS/ME
increased levels of neutrophil apoptosis occurs in some patients
[49,50,51], and this potentially ensues from high levels of miR-
143-3p.
MiR-127-3p interferes with ERK signalling, a tumour suppres-
sor and upregulations have been shown to increase apoptosis [52].
Importantly, it targets BCL6 a transcription factor which increases
p53 expression [53]. BCL6 inhibits the production of IL-10
therefore by dampening BCL6 as a consequence of miR-127
upregulation may result in significant increases in IL-10 [54]. In
CFS/ME equivocal levels of IL-10 have been reported and an
over expression of miR-127-3p may explain to some extent some
of these patterns. BCL6 is an important transcription factor
required for germinal centre B cell and follicular helper T cell
development [55,56,57]. Irregularities in the expression of BCL6
may result in aberrant inflammatory responses and the develop-
ment of various lymphomas [58].
The presence of a high proportion of the RNA Y4 within the
small RNA sequencing libraries reduced miRNA sequencing
capacity. Y RNAs are components of Ro ribonucleoproteins
(RNPs) and were first identified in the serum of patients with the
autoimmune disorder lupus erythematosus [59]. Y RNAs are
similar in size and structure to miRNAs as they both have
comparable stem and loop structures [60]. These similarities may
explain the presence of Y RNA following small RNA library
construction. Efficient depletion of Y RNA would yield higher
quality HTS miRNA data allowing deeper sequencing. Methods
for the reduction of Y RNA in a similar manner to rRNA
depletion could be employed to improve the ratio of useful
miRNA data [61]. Most extracellular miRNA studies do not
report on the abundance of Y RNAs in circulation and this may be
related to the read size filtering used. Given that Y RNAs upon
degradation produce two classes of fragments and majority of
which bind to Ro60, it is possible to posit that these fragments that
we observed in the plasma samples are those Y RNAs bound to
Ro60.
Plasma miRNAs show great promise as potential non-invasive
biomarkers, but at present the precise and accurate measurement
is challenging. A number of factors including cellular contamina-
tion, haemolysis and low quantity can result in significant bias that
does not reflect the original biological state of the sample. Current
circulating miRNA research indicates that haemolysis may
influence the availability of miRNAs in circulation [33]. Haemo-
lysis may be evaluated in archival data by examining the delta Cq
of miR-451 and miR-23a [33]. In healthy individuals, 194
miRNAs may be detected in both haemolysed and non-
haemolysed blood samples, where 40.2% may be upregulated
following haemolysis, 13% may be down regulated and 28.9% are
unaffected by haemolysis [62,63]. In the present study, our three
candidate miRNAs, miR-127-3p, miR-143-3p and miR-142-5p
are among the miRNA genes unaffected by haemolysis in healthy
individuals [62].
The benefit of circulating miRNAs as biomarkers for diseases
relates to a number of characteristics such as reduced complexity
compared to proteins, stability, conserved sequences in various
species and restricted expression in specific tissues and biological
processes. It has been suggested that 206 miRNAs are expressed in
blood cells, serum and plasma, thus in most plasma and serum
studies it is highly necessary to observe strict sample processing
procedures to ensure the samples are cell free [64]. Cellular
content contamination of biofluids may be reduced by employing
additional centrifugation steps during the initial plasma separation
to lessen potential contamination from cellular debris and
haemolysis [65]. Additionally, it may be important to assess blood
cell counts and lysis during sample collection as variation in
plasma levels of miRNAs in some cases have been credited to
circulating blood cell effects [66,67]. Starting concentration of
miRNA levels vary among individuals due to age, sex and other
factors and this may significantly impact the outcomes of various
expression studies [68,69]. To date there are no established
reference values for miRNAs among normal individuals and this
may be necessary for diagnostic marker purposes, hence, the
inclusion of appropriate calibrator controls during RT-qPCR
analysis is necessary. Nonetheless, despite these challenges,
miRNA signatures from normal individuals are reproducible with
similar expression patterns and a limited amount of variability
[32,70].
Figure 3. Relative expression data presented as boxplots for
miRNAs identified as differentially expressed by Illumina HTS.
Boxes indicate the interquartile range (25%–75%) with the horizontal
bar within each box indicating the media. The whiskers show the
minimum and maximum values. *P,0.05 vs. non-fatigued control
(n = 20/group).
doi:10.1371/journal.pone.0102783.g003
Circulating MiRNAs in CFS/ME
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e102783
Conclusions
The present study suggests that plasma may be a satisfactory
parameter for determining miRNAs as biomarkers in CFS/ME.
The data illustrates that miR-127-3p, miR-142-5p and miR-
143-3p may be potential plasma biomarkers for CFS/ME
diagnosis. However, further studies are now required to validate
these findings in a larger cohort to ascertain diagnostic power of
these findings. The shortcomings with using biofluid is the low
abundance of RNA thus a large quantity of sample is often
required to achieve high yields and quality of RNA. Presently,
the use of HTS as a means to detecting possible changes in
miRNAs in disease presentations is in its infancy. Further studies
are required to evaluate and refine the method to promote
better detection and reliable data that can be replicated across
studies.
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